Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.56 |
| ▸ | EGFR | P00533 | 12/20 | 0.45 |
| ▸ | ITK | Q08881 | 5/20 | 0.45 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL657015 | 1.00 | SYK (0.56) | SYKEGFRITKBTK | |
| SCHEMBL657558 | 0.97 | SYK (0.59) | SYKEGFRITKBTK | |
| Hydrochloric Acid SCHEMBL656794 | 0.96 | SYK (0.58) | SYKEGFRITKBTK | |
| Succinic Acid SCHEMBL657780 | 0.94 | SYK (0.57) | SYKEGFRITKBTK | |
| Citric Acid SCHEMBL656798 | 0.90 | SYK (0.53) | SYKEGFRITKBTK | |
| SCHEMBL654902 | 0.89 | SYK (0.49) | SYKEGFRITKBTK | |
| SCHEMBL658177 | 0.86 | SYK (0.48) | SYKEGFRITKBTK | |
| SCHEMBL3838404 | 0.85 | SYK (0.49) | SYKEGFRITKBTK | |
| SCHEMBL3839325 | 0.80 | EGFR (0.46) | SYKEGFRITKBTK | |
| SCHEMBL3836417 | 0.79 | EGFR (0.55) | SYKEGFRITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8148525-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120045454-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| EP-1471915-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2281563-A1 | 2,4-Pyrimidinediamine compounds and their uses | Rigel Pharmaceuticals, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045454-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | SYK 54/4885EGFR 903/4885ITK 911/4885 |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | FCER2, FCGR1A, FCGR2A | SYK 54/4885EGFR 903/4885ITK 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.